Lok Sabha Question No. 5601 (UNSTARRED), answered on 2026-03-27
Subject: Production Linked Incentive Scheme for Pharmaceuticals
Ministry: CHEMICALS AND FERTILIZERS
Asked by: Shri Krishna Prasad Tenneti, Shri Bhartruhari Mahtab, Shri Madhavaneni Raghunandan Rao, Shri Bibhu Prasad Tarai, Shri Naba Charan Majhi, Shri Haribhai Patel, Shri Chandra Prakash Choudhary, Smt. Aparajita Sarangi

## GOVERNMENT OF INDIA MINISTRY OF CHEMICALS AND FERTILIZERS DEPARTMENT OF PHARMACEUTICALS

## LOK SABHA

UNSTARRED QUESTION NO. 5601

TO BE ANSWERED ON THE

27 TH  MARCH 2026

## Production Linked Incentive Scheme for Pharmaceuticals

## 5601.   Shri Bhartruhari Mahtab:

Shri Haribhai Patel:

Smt. Aparajita Sarangi:

Shri Chandra Prakash Choudhary:

Shri Krishna Prasad Tenneti:

Shri Naba Charan Majhi:

Shri Madhavaneni Raghunandan Rao:

Shri Bibhu Prasad Tarai:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) the progress made under the PLI Scheme for Bulk Drugs in reducing India's import dependency on critical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs);
- (b) the details of the forty-one identified products for which domestic manufacturing capacities have been successfully established under the greenfield project model;
- (c) the status of the three Bulk Drug Parks being developed in Himachal Pradesh, Gujarat, and Andhra Pradesh and the common infrastructure facilities provided therein, State-wise;
- (d) whether the PLI Scheme for Pharmaceuticals has incentivized the production of high-value goods such as bio-pharmaceuticals, complex generics and patented drugs, if so, the details thereof; and
- (e) the total cumulative investment attracted and the number of direct and indirect employment opportunities  generated  in  the  pharmaceutical  sector  since  the  launch  of  the  said  schemes, yearwise?

## ANSWER

## THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS

(SMT. ANUPRIYA PATEL)

(a)  and  (b):  The  status  of  implementation  of  Production  Linked  Incentive  (PLI)  Scheme  for promotion  of  domestic  manufacturing  of  critical  Key  Starting  Materials  (KSMs)  /  Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as 'PLI scheme for Bulk Drugs') is as follows:

i. Till December 2025, investment of ₹4,814 crore has been made against an investment commitment of ₹4,329.95 crore in greenfield projects.

ii.  Total  capacity  amounting  to  91,077  metric  tonnes  per  annum  is  committed  for  33 subscribed products as against originally envisaged capacity of 82,270 metric tonnes per annum for 41 products identified (List of 41 products is  placed at  Annexure) . Further, manufacturing capacity of 56,800 metric tonnes per annum has been created for 28 critical KSMs, DIs, and APIs till December, 2025. The scheme has resulted in cumulative sales of ₹2,720 crore, including exports of ₹527.96 crore s.

(c): Department  of  Pharmaceuticals  is  implementing  a  scheme,  namely  the  scheme  for Promotion of Bulk Drug Parks, with a budgetary outlay of ₹3,000 crore, under which three bulk drug parks have been approved and are at various stages of development in the States of Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective State implementing agencies. The total project cost of these parks is over ₹6,306.68 crore, with Central assistance to the tune of ₹1,000 crore each for creation of common infrastru cture facilities. These parks envisage land and utilities  such  as  power,  water,  effluent  treatment  plant,  steam,  solid  waste  management  and warehouse facilities at a subsidised rate to bulk drug or API manufacturers for units set up in the park. The State implementing agencies of the States concerned have also offered fiscal incentives in  the  form  of  capital  subsidy  on  fixed  capital  investment,  interest  subsidy,  State  Goods  and Services Tax reimbursement, exemption of stamp duty and registration charges, etc. Further, the scheme provides for applicants for allotment of land in the parks to set up units for manufacturing products prioritised in the PLI Scheme for Bulk Drugs to have priority in land allotment.

(d): The Production Linked Incentive (PLI) scheme aims to enhance India's  manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing  to  product  diversification  to  high-value  goods  in  the  pharmaceutical  sector  and incentivises  production  of  high-value  medicines  such  as  biopharmaceuticals,  complex  generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc.

(e): The total cumulative investment attracted and the number of direct and indirect employment opportunities generated in the pharmaceutical sector since the launch of the said schemes, yearwise is given below:

|                                | Cumulative i nvestment (in crore ₹) till   | Cumulative i nvestment (in crore ₹) till   | Cumulative i nvestment (in crore ₹) till   | Cumulative i nvestment (in crore ₹) till   | Employment (Nos.) opportunities generated till   | Employment (Nos.) opportunities generated till   | Employment (Nos.) opportunities generated till   | Employment (Nos.) opportunities generated till   |
|--------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                | March 2023                                 | March 2024                                 | March 2025                                 | December 2025                              | March 2023                                       | March 2024                                       | March 2025                                       | December 2025                                    |
| PLI Scheme for Bulk Drugs      | 2,374.93                                   | 3,721.44                                   | 4,554.25                                   | 4,814.10                                   | 2,163                                            | 3,538                                            | 4,490                                            | 4,896                                            |
| PLI Scheme for Pharmaceuticals | 20,647                                     | 29,268                                     | 37,306.65                                  | 42,694.89                                  | 46,357                                           | 70,362                                           | 93,532                                           | 1,13,300                                         |

Annexure referred to in reply to parts (a) and (b) of the Lok Sabha Unstarred Question No. 5601, to be answered on 27.3.2026

|   S. No. | Name of Products covered under PLI Scheme for Bulk Drugs   |
|----------|------------------------------------------------------------|
|        1 | Penicillin G                                               |
|        2 | 7-ACA                                                      |
|        3 | Clavulanic Acid                                            |
|        4 | Erythromycin Thiocyanate (TIOC)                            |
|        5 | Betamethasone                                              |
|        6 | Dexamethasone                                              |
|        7 | Prednisolone                                               |
|        8 | Rifampicin                                                 |
|        9 | Clindamycin Base                                           |
|       10 | Streptomycin                                               |
|       11 | Tetracycline                                               |
|       12 | Neomycin                                                   |
|       13 | Gentamycin                                                 |
|       14 | Para Amino Phenol                                          |
|       15 | 1,1 Cyclohexane Diacetic Acid (CDA)                        |
|       16 | Dicyandiamide (DCDA)                                       |
|       17 | 2-Methyl-5-Nitro-Imidazole (2-MNI)                         |
|       18 | Meropenem                                                  |
|       19 | Atorvastatin                                               |
|       20 | Olmesartan                                                 |
|       21 | Valsartan                                                  |
|       22 | Losartan                                                   |
|       23 | Levofloxacin                                               |
|       24 | Sulfadiazine                                               |
|       25 | Ofloxacin                                                  |
|       26 | Norfloxacin                                                |
|       27 | Artesunate                                                 |
|       28 | Telmisartan                                                |
|       29 | Aspirin                                                    |
|       30 | Levetiracetam                                              |
|       31 | Carbidopa                                                  |
|       32 | Ritonavir                                                  |
|       33 | Lopinavir                                                  |
|       34 | Acyclovir                                                  |
|       35 | Carbamazepine                                              |
|       36 | Oxcarbazepine                                              |
|       37 | Vitamin B6                                                 |

|   38. | Levodopa          |
|-------|-------------------|
|    39 | Vitamin B1        |
|    40 | Diclofenac Sodium |
|    41 | Ciprofloxacin     |

******